Bioventus Inc. (NYSE:BVS) Shares Acquired by Barclays PLC

Barclays PLC raised its position in shares of Bioventus Inc. (NYSE:BVS) by 24.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 50,654 shares of the company’s stock after purchasing an additional 9,854 shares during the quarter. Barclays PLC owned about 0.06% of Bioventus worth $606,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Virtus Fund Advisers LLC bought a new position in Bioventus during the third quarter valued at about $42,000. Quest Partners LLC bought a new position in shares of Bioventus during the 3rd quarter valued at about $51,000. Quarry LP bought a new stake in shares of Bioventus in the 3rd quarter worth approximately $59,000. Covestor Ltd acquired a new stake in Bioventus during the third quarter valued at approximately $69,000. Finally, CWM LLC bought a new stake in Bioventus during the third quarter worth approximately $89,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on BVS shares. Craig Hallum increased their price objective on Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, September 27th. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and increased their price target for the company from $12.00 to $13.00 in a research report on Tuesday, December 17th. Finally, Canaccord Genuity Group boosted their price objective on Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th.

Insider Buying and Selling at Bioventus

In other news, SVP Katrina J. Church sold 2,535 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $10.53, for a total transaction of $26,693.55. Following the completion of the sale, the senior vice president now directly owns 47,264 shares of the company’s stock, valued at $497,689.92. This trade represents a 5.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Mark Leonard Singleton sold 10,733 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total value of $113,018.49. Following the completion of the sale, the chief financial officer now directly owns 105,162 shares of the company’s stock, valued at approximately $1,107,355.86. The trade was a 9.26 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 32.90% of the company’s stock.

Bioventus Price Performance

BVS opened at $10.50 on Thursday. The firm has a market capitalization of $852.13 million, a P/E ratio of -17.21 and a beta of 0.79. The stock has a fifty day moving average of $11.72 and a 200-day moving average of $9.90. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 12-month low of $3.90 and a 12-month high of $14.38.

Bioventus (NYSE:BVS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. The firm had revenue of $138.96 million during the quarter, compared to the consensus estimate of $132.57 million. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. During the same period in the prior year, the business earned $0.05 EPS. Equities analysts forecast that Bioventus Inc. will post 0.41 EPS for the current fiscal year.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.